W. Fett

Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups

Michael Untch, Peter A. Fasching, Gottfried E. Konecny et al. · Journal of Clinical Oncology · 2011 · 508 citations

Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials

Gunter von Minckwitz, Michael Untch, Eveline Nüesch et al. · Breast Cancer Research and Treatment · 2010 · 276 citations · Full text

Breast Oncology, Medicine, Clinical Trials +6

Combined preoperative chemotherapy and radiotherapy in patients with locally advanced esophageal cancer. Interim analysis of a phase II trial.

M. Stahl, H. Wilke, U. Fink et al. · Journal of Clinical Oncology · 1996 · 147 citations

PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer—results at the time of surgery

Michael Untch, Peter A. Fasching, Gottfried E. Konecny et al. · Annals of Oncology · 2011 · 133 citations

Surgical Oncology, Breast Oncology, Standard-dosed Epirubicin/cyclophosphamide +9

PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin–cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer—outcome on prognosis

Michael Untch, Gϋnter von Minckwitz, Gottfried E. Konecny et al. · Annals of Oncology · 2011 · 121 citations

Darbepoetin Alfa, Breast Oncology, Medicine +7